BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,371,715 | -32.3% | 20,152 | -18.8% | 0.00% | -20.0% |
| Q2 2023 | $2,026,427 | +188580.4% | 24,826 | +71.2% | 0.01% | +66.7% |
| Q1 2023 | $1,074 | -20.1% | 14,498 | -10.7% | 0.00% | -25.0% |
| Q4 2022 | $1,345 | -99.8% | 16,230 | +444.1% | 0.00% | +33.3% |
| Q3 2022 | $847,000 | -92.2% | 2,983 | -90.5% | 0.00% | -93.3% |
| Q2 2022 | $10,897,000 | -18.4% | 31,435 | +1.9% | 0.04% | -10.0% |
| Q1 2022 | $13,357,000 | +76.0% | 30,846 | +7.3% | 0.05% | -34.2% |
| Q2 2020 | $7,589,000 | +42.9% | 28,739 | +2.6% | 0.08% | +15.2% |
| Q1 2020 | $5,310,000 | -13.6% | 28,004 | -0.0% | 0.07% | +3.1% |
| Q4 2019 | $6,148,000 | +12.1% | 28,006 | -0.1% | 0.06% | -3.0% |
| Q3 2019 | $5,484,000 | -6.1% | 28,029 | +0.0% | 0.07% | -5.7% |
| Q2 2019 | $5,843,000 | +5.4% | 28,027 | +0.4% | 0.07% | -11.4% |
| Q1 2019 | $5,545,000 | +37.3% | 27,928 | +0.1% | 0.08% | +9.7% |
| Q4 2018 | $4,039,000 | -29.1% | 27,911 | +0.1% | 0.07% | -50.7% |
| Q3 2018 | $5,694,000 | +36.4% | 27,896 | -1.1% | 0.15% | +23.7% |
| Q2 2018 | $4,173,000 | -1.3% | 28,205 | +0.7% | 0.12% | -22.4% |
| Q1 2018 | $4,230,000 | – | 28,009 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |